From @Breakingviews: Moderna turned cutting-edge science into a best-selling product in two years. @rob_cyran explains how its $94 billion valuation is based less on its COVID-19 vaccine than faith that it can do this again repeatedly – and how competition might be a problem pic.twitter.com/KHEe188Uup— Reuters (@Reuters) January 6, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


